
HYUNDAI BIOSCIENCE CO., LTD. — Investor Relations & Filings
HYUNDAI BIOSCIENCE CO., LTD. is a biotechnology company focused on developing innovative therapeutics using its proprietary drug delivery system (DDS) technology. The company's core science is based on organic-inorganic hybrid technologies designed to safely and effectively deliver active ingredients. Its main development pipeline includes CP-COV03, a broad-spectrum antiviral agent that enhances cellular autophagy to combat viral infections, and Polytaxel, an anticancer drug candidate developed with polymer transfer technologies to reduce toxicity. The company's primary focus is on creating novel treatments for viral diseases and cancer.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 분기보고서 (2026.03) | 2026-05-15 | Korean | |
| 주식등의대량보유상황보고서(일반) | 2026-04-23 | Korean | |
| 투자판단관련주요경영사항(임상시험계획변경승인) (전립선암 치료제 CPPCA07의 1상 임상시험계획 변경승인) | 2026-04-17 | Korean | |
| [기재정정]사업보고서 (2025.12) | 2026-03-30 | Korean | |
| 정기주주총회결과 | 2026-03-26 | Korean | |
| 주식등의대량보유상황보고서(일반) | 2026-03-26 | Korean |
Browse filings by year
9 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 46358854 | 분기보고서 (2026.03) | 2026-05-15 | Korean | ||
| 35617450 | 주식등의대량보유상황보고서(일반) | 2026-04-23 | Korean | ||
| 34652991 | 투자판단관련주요경영사항(임상시험계획변경승인) (전립선암 치료제 CPPCA07의 1상 임상시험계획 변경승인) | 2026-04-17 | Korean | ||
| 33085693 | [기재정정]사업보고서 (2025.12) | 2026-03-30 | Korean | ||
| 33048902 | 정기주주총회결과 | 2026-03-26 | Korean | ||
| 33045906 | 주식등의대량보유상황보고서(일반) | 2026-03-26 | Korean | ||
| 32971201 | 사업보고서 (2025.12) | 2026-03-18 | Korean | ||
| 32963400 | 감사보고서제출 | 2026-03-17 | Korean | ||
| 32934747 | 주식등의대량보유상황보고서(약식) | 2026-03-12 | Korean | ||
| 32928311 | [기재정정]주주총회소집공고 | 2026-03-11 | Korean | ||
| 32926691 | 주주총회소집결의 | 2026-03-11 | Korean | ||
| 32926657 | 주주총회소집공고 | 2026-03-11 | Korean | ||
| 32926634 | 의결권대리행사권유참고서류 | 2026-03-11 | Korean | ||
| 32908238 | 투자판단관련주요경영사항(임상시험계획변경승인신청) (전립선암 치료제 CPPCA07의 1상 임상시험계획 변경승인 신청) | 2026-03-06 | Korean | ||
| 32907424 | 주식등의대량보유상황보고서(일반) | 2026-03-06 | Korean | ||
Market data
Market data not available
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
Alpha Tau Medical Ltd.
Clinical-stage oncology firm developing alpha radiation the…
|
DRTS | US | Professional, scientific and te… |
|
Alteogen Inc.
Biopharmaceutical firm developing biologics with proprietar…
|
196170 | KR | Professional, scientific and te… |
|
ALTERITY THERAPEUTICS LIMITED
Clinical-stage developer of disease-modifying therapies for…
|
ATH | AU | Professional, scientific and te… |
|
AlzeCure Pharma
Develops therapies for severe diseases, focusing on Alzheim…
|
ALZCUR | SE | Professional, scientific and te… |
|
AMPLIA THERAPEUTICS LIMITED
Clinical-stage developer of FAK inhibitors for solid tumors…
|
ATX | AU | Professional, scientific and te… |
|
ANAPTYSBIO, INC
Clinical-stage biotech developing immunology therapeutics f…
|
ANAB | US | Professional, scientific and te… |
|
ANATARA LIFESCIENCES LTD
Develops non-antibiotic gastrointestinal health solutions f…
|
ANR | AU | Professional, scientific and te… |
|
AngioLab, Inc.
Develops angiogenesis inhibitors for pharmaceuticals and he…
|
251280 | KR | Professional, scientific and te… |
|
Anhui Wanbang Pharmaceutical Technology Co.,Ltd.
Pharmaceutical CRO specializing in clinical trials, BE stud…
|
301520 | CN | Professional, scientific and te… |
|
Anixa Biosciences Inc
A clinical-stage biotech developing therapies and vaccines …
|
ANIX | US | Professional, scientific and te… |
HYUNDAI BIOSCIENCE CO., LTD. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/16484/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=16484 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=16484 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=16484 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 16484}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for HYUNDAI BIOSCIENCE CO., LTD. (id: 16484)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.